The science in plain English
Plain-English explainers on GLP-1 nutrition, muscle preservation, side effects and the newest research on Ozempic, Wegovy, Mounjaro and Zepbound. No hype - just what the evidence says.
How much weight can you lose on Foundayo?
Foundayo (orforglipron), the first oral non-peptide GLP-1 pill, was FDA-approved April 1, 2026. Its pivotal trial showed up to 11.1% average weight loss at 72 weeks.
Can semaglutide help people with schizophrenia lose weight?
A CAMH trial is testing weekly semaglutide in 92 adults with schizophrenia who did not respond to metformin, tracking psychiatric symptoms alongside weight.
Retatrutide and TRIUMPH-1: what we know so far
Eli Lilly's triple-agonist hit 24.2% weight loss at 48 weeks in Phase 2. Its Phase 3 trial TRIUMPH-1 has finished, but no results are posted yet.
Can MariTide treat heart failure and obesity?
Amgen's Phase 3 MARITIME-HF trial tests MariTide, a once-monthly GLP-1 agonist and GIP antagonist, in ~5,056 people with obesity and heart failure. Recruiting now - no results yet.
Can tirzepatide help breast cancer survivors lose weight?
Rutgers' FITWISE trial gives 40 breast cancer survivors with obesity weekly tirzepatide, tracking weight loss and 3-year recurrence risk. Recruiting now - no results yet.
Can tirzepatide help people with type 1 diabetes and obesity?
Eli Lilly's SURPASS-T1D-2 trial tests weekly tirzepatide vs. placebo in adults with type 1 diabetes. No results yet.
Tirzepatide vs semaglutide for HFpEF: what's being studied
A 26,000-patient claims-data study compares tirzepatide and semaglutide in type 2 diabetes with HFpEF. No results yet.
Does tirzepatide protect muscle and bone in older adults?
A Wake Forest pilot trial is giving 40 adults over 65 weekly tirzepatide plus protein counseling for 9 months. No results yet.
Can GLP-1 drugs slow biological aging?
A 66-person trial in China is testing whether semaglutide or tirzepatide slow epigenetic aging more than metformin. Recruiting now - no results yet.
Bariatric surgery vs. semaglutide vs. tirzepatide
A Cleveland Clinic trial of 125 adults is running the first head-to-head comparison of bariatric surgery against semaglutide and tirzepatide. Underway now - no results yet.
Can a high-protein diet stop GLP-1 muscle loss?
A new randomized trial of 130 adults in Greece is testing whether high dietary protein preserves more muscle than standard counseling during GLP-1 treatment. Recruiting now - no results yet.
Semaglutide vs tirzepatide: which protects the heart more?
A 2026 real-world study of 21,250 patients found semaglutide cut major cardiovascular events by 22-29% versus tirzepatide - though the study was funded by semaglutide's maker.
How much muscle do you lose on GLP-1 drugs?
A 2025 meta-analysis of 22 RCTs puts the number at 0.86 kg - about 24% of total weight lost. What it means for Ozempic, Wegovy, Mounjaro, and Zepbound users.
Does semaglutide protect your heart? What 22,937 patients show
A 2025 meta-analysis of 10 RCTs found semaglutide cuts heart attack risk by 28%, atrial fibrillation risk by 21%, and angina risk by 23%. What Ozempic and Wegovy users need to know.
Tirzepatide vs semaglutide: which drug loses more weight?
Two independent 2025 meta-analyses covering 142,000+ patients show tirzepatide (Mounjaro, Zepbound) outperforms semaglutide (Ozempic, Wegovy) by roughly 4 kg on average - a gap that grows at higher doses.
Does tirzepatide protect the kidneys better than dulaglutide?
A pre-specified analysis of the SURPASS-CVOT trial in 13,299 patients found tirzepatide cut major kidney events by 23% versus dulaglutide - though Eli Lilly funded the trial and makes both drugs.
Be first to repair your nutritional gaps
Keep the weight loss. Fill the nutritional gap